Covid-19 third vaccination during pregnancy: maternal and neonatal outcomes-a retrospective study.
Booster dose
Covid-19 vaccine
Health care coverage
Outcome
Pregnancy
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
15
06
2022
accepted:
04
09
2022
medline:
18
8
2023
pubmed:
27
9
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
To evaluate the impact of Covid-19 (Pfizer-BioNTech BNT162b2) third booster dose vaccination during pregnancy on maternal and neonatal outcomes. This is a multicenter, retrospective computerized database study. Parturients who delivered in Israel between August and December 2021 with full records of Covid-19 disease and vaccination status were included. Those who received third booster during pregnancy were compared to those who received two doses of vaccine during pregnancy and to unvaccinated parturients. Various adverse maternal and neonatal outcomes were evaluated. Parturients who were previously positive with Covid-19 PCR swabs during pregnancy or before pregnancy were excluded. Univariate analysis was followed by multivariate analysis. A total of 2583 women were included in the analysis; 626 received the third booster dose of the BNT162b2 Covid-19 vaccine, 1094 received two doses of the vaccine, and 863 unvaccinated women. Maternal and neonatal outcomes were comparable between the study groups. An adjusted multivariable logistic regression analysis demonstrated that receiving the third booster was not associated with an increase in neither composite adverse maternal or neonatal outcome (aOR 0.9; 95% CI [0.65-1.22], p = 0.47; aOR 0.7; 95% CI [0.53-1.035], p= 0.09, respectively) when compared to those who received two doses of the vaccine. However, administration of the third booster dose during pregnancy was associated with a reduced composite adverse neonatal outcome when compared to unvaccinated women (aOR 0.6; 95% CI [0.42-0.86], p = 0.01). Receiving the third booster dose of the BNT162b2 Covid-19 vaccine during pregnancy is not associated with an increased risk of any adverse maternal outcomes and may be beneficial for the neonates.
Identifiants
pubmed: 36155854
doi: 10.1007/s00404-022-06786-9
pii: 10.1007/s00404-022-06786-9
pmc: PMC9513010
doi:
Substances chimiques
BNT162 Vaccine
0
COVID-19 Vaccines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197-1205Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Khedmat L, Mohaghegh P, Veysizadeh M, Hosseinkhani A, Fayazi S, Mirzadeh M (2022) Pregnant women and infants against the infection risk of COVID-19: a review of prenatal and postnatal symptoms, clinical diagnosis, adverse maternal and neonatal outcomes, and available treatments. Arch Gynecol Obstet 306(2):323–335
doi: 10.1007/s00404-021-06325-y
pubmed: 34842975
Delahoy MJ, Whitaker M, O’Halloran A, Chai SJ, Kirley PD, Alden N et al (2020) Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19—COVID-NET, 13 states, March 1–August 22, 2020. Morb Mortal Wkly Rep 69(38):1347
doi: 10.15585/mmwr.mm6938e1
Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT et al (2020) Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. Morb Mortal Wkly Rep 69(44):1641
doi: 10.15585/mmwr.mm6944e3
Woodworth KR, Olsen EO, Neelam V, Lewis EL, Galang RR, Oduyebo T et al (2020) Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy—SET-NET, 16 jurisdictions, March 29–October 14, 2020. Morb Mortal Wkly Rep 69(44):1635
doi: 10.15585/mmwr.mm6944e2
Mirbeyk M, Saghazadeh A, Rezaei N (2021) A systematic review of pregnant women with COVID-19 and their neonates. Arch Gynecol Obstet 304(1):5–38
doi: 10.1007/s00404-021-06049-z
pubmed: 33797605
pmcid: 8017514
Antoun L, El Taweel N, Ahmed I, Patni S, Honest H (2020) Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: a prospective cohort study. Eur J Obstet Gynecol Reprod Biol 252:559–562
doi: 10.1016/j.ejogrb.2020.07.008
pubmed: 32732059
pmcid: 7362841
Ahlberg M, Neovius M, Saltvedt S, Söderling J, Pettersson K, Brandkvist C et al (2020) Association of SARS-CoV-2 test status and pregnancy outcomes. JAMA 324(17):1782–1785
doi: 10.1001/jama.2020.19124
pubmed: 32965467
pmcid: 7512127
Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T et al (2020) Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. https://doi.org/10.1136/bmj.m3320
doi: 10.1136/bmj.m3320
pubmed: 32873575
Ferrer-Oliveras R, Mendoza M, Capote S, Pratcorona L, Esteve-Valverde E, Cabero-Roura L et al (2021) Immunological and physiopathological approach of COVID-19 in pregnancy. Arch Gynecol Obstet 304(1):39–57
doi: 10.1007/s00404-021-06061-3
pubmed: 33945026
pmcid: 8093597
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
Pregnant women: scientific and ethical considerations for inclusion in clinical trials guidance for industry. [cited 2021 Apr 25]. https://www.fda.gov/files/drugs/published/Pregnant-Women--Scientific-and-Ethical-Considerations-for-Inclusion-in-Clinical-Trials.pdf . Accessed 25 April 2021
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S et al (2021) Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 385(24):e84
doi: 10.1056/NEJMoa2114583
pubmed: 34614326
Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2021) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385(19):1761–1773
doi: 10.1056/NEJMoa2110345
pubmed: 34525277
Rottenstreich M, Sela HY, Rotem R, Kadish E, Wiener-Well Y, Grisaru-Granovsky S (2022) Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. BJOG 129(2):248–255
doi: 10.1111/1471-0528.16941
pubmed: 34554630
Dick A, Rosenbloom JI, Gutman-Ido E, Lessans N, Cahen-Peretz A, Chill HH (2022) Safety of SARS-CoV-2 vaccination during pregnancy—obstetric outcomes from a large cohort study. BMC Pregnancy Childbirth 22(1):166
doi: 10.1186/s12884-022-04505-5
pubmed: 35227233
pmcid: 8884102
Blakeway H, Prasad S, Kalafat E, Heath PT, Ladhani SN, Le Doare K et al (2022) COVID-19 vaccination during pregnancy: coverage and safety. Am J Obstet Gynecol 226(2):236.e1-236.e14
doi: 10.1016/j.ajog.2021.08.007
pubmed: 34389291
Kalafat E, Magee LA, von Dadelszen P, Heath P, Khalil A (2022) COVID-19 booster doses in pregnancy and global vaccine equity. Lancet. https://doi.org/10.1016/S0140-6736(22)00166-0
doi: 10.1016/S0140-6736(22)00166-0
pubmed: 35189078
pmcid: 8856664
Wainstock T, Yoles I, Sergienko R, Sheiner E (2021) Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine 39(41):6037–6040
doi: 10.1016/j.vaccine.2021.09.012
pubmed: 34531079
pmcid: 8421099
Lipkind HS, Vazquez-Benitez G, DeSilva M, Vesco KK, Ackerman-Banks C, Zhu J et al (2022) Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth—eight integrated health care organizations, United States, December 15, 2020–July 22, 2021. MMWR Morb Mortal Wkly Rep 71(1):26–30
doi: 10.15585/mmwr.mm7101e1
pubmed: 34990445
pmcid: 8735559
Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK et al (2022) Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA. https://doi.org/10.1001/jama.2022.4255
doi: 10.1001/jama.2022.4255
pubmed: 35499852
pmcid: 9062768
Schaal NK, Zöllkau J, Hepp P, Fehm T, Hagenbeck C (2022) Pregnant and breastfeeding women’s attitudes and fears regarding the COVID-19 vaccination. Arch Gynecol Obstet 306(2):365–372
doi: 10.1007/s00404-021-06297-z
pubmed: 34705115
Bookstein Peretz S, Regev N, Novick L, Nachshol M, Goffer E, Ben-David A et al (2021) Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol 58(3):450–456
doi: 10.1002/uog.23729
pubmed: 34198360
pmcid: 8441755
Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G et al (2021) Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. JAMA 326(8):728–735
doi: 10.1001/jama.2021.11035
pubmed: 34251417
pmcid: 8276131
Moreira EDJ, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A et al (2022) Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. https://doi.org/10.1056/NEJMoa2200674
doi: 10.1056/NEJMoa2200674
pubmed: 35320659
pmcid: 9006787
COVID A. Vaccination Considerations for Obstetric–Gynecologic Care. Online (Stand: 18.11. 2021): https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-forobstetric-gynecologic-care
Yang YJ, Murphy EA, Singh S, Sukhu AC, Wolfe I, Adurty S et al (2022) Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 139(3):373–380
doi: 10.1097/AOG.0000000000004693
pubmed: 34963127
Hameed I, Khan MO, Nusrat K, Mahmood S, Nashit M, Malik S et al (2022) Is it safe and effective to administer COVID-19 vaccines during pregnancy a systematic review and meta-analysis. Am J Infect Control. https://doi.org/10.1016/j.ajic.2022.08.014
doi: 10.1016/j.ajic.2022.08.014
pubmed: 36007670
pmcid: 9394101
Dick A, Rosenbloom JI, Karavani G, Gutman-Ido E, Lessans N, Chill HH (2022) Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy. Am J Obstet Gynecol MFM 4(4):100637
doi: 10.1016/j.ajogmf.2022.100637
pubmed: 35398583
pmcid: 8988438
Lemon L, Edwards RP, Simhan HN (2021) What is driving the decreased incidence of preterm birth during the coronavirus disease 2019 pandemic? Am J Obstet Gynecol MFM 3(3):100330
doi: 10.1016/j.ajogmf.2021.100330
pubmed: 33618035
pmcid: 10283084
Rottenstreich A, Zarbiv G, Oiknine-Djian E, Vorontsov O, Zigron R, Kleinstern G et al (2022) Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study. Clin Microbiol Infect 28(3):419–425
doi: 10.1016/j.cmi.2021.10.003
pubmed: 34740773
Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Håberg SE (2021) Covid-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med 385(21):2008–2010
doi: 10.1056/NEJMc2114466
pubmed: 34670062
Goldshtein I, Steinberg DM, Kuint J, Chodick G, Segal Y, Shapiro Ben David S et al (2022) Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes. JAMA Pediatr. https://doi.org/10.1001/jamapediatrics.2022.0001
doi: 10.1001/jamapediatrics.2022.0001
pubmed: 35639390
pmcid: 8832306